Literature DB >> 27796250

Prevalence of diagnosed ocular disease in veterans with serious mental illness.

Osamah Saeedi1, Hasan Ashraf2, Marc Malouf3, Eric P Slade4, Deborah R Medoff4, Lan Li5, Julie Kreyenbuhl4.   

Abstract

OBJECTIVE: To compare the prevalence of diagnosed ocular disease and eye disease treatment between Veteran's Administration (VA) patients with and without serious mental illness (SMI).
METHODS: Retrospective comparison of diagnosed ocular disease and treatment prevalence among patients with and without diagnosed SMI in fiscal year 2011 in the VA Capitol Health Care System (VISN 5).
RESULTS: We identified 6462 VA patients with SMI and 137,933 without SMI. The prevalence of diagnosed ocular disease was 22.7% in SMI patients and 35.4% in non-SMI patients (P<.001). Those with SMI had a higher prevalence of glaucoma (10.2% vs. 7.1%, P<.0001), cataract (12.6% vs. 9.2%, P<.0001) and dry eye (4.0% vs. 2.7%, P<.0001). Less than half (34.3%) of SMI subjects had been seen in ophthalmology or optometry vs. 23.0% of controls (P<.0001).
CONCLUSION: VA patients with SMI have a greater prevalence of diagnosed ocular disease, particularly cataract, glaucoma and dry eye. While SMI patients utilize eye care services at a higher rate than the general VA population, the majority of subjects with SMI do not get recommended annual eye examinations. More consistent annual ocular screening among VA patients with SMI may be indicated.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cataract; Epidemiology; Glaucoma; Ocular disease; Severe mental illness; Veteran

Mesh:

Year:  2016        PMID: 27796250      PMCID: PMC5111362          DOI: 10.1016/j.genhosppsych.2016.08.003

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  28 in total

1.  Mental disorders and use of cardiovascular procedures after myocardial infarction.

Authors:  B G Druss; D W Bradford; R A Rosenheck; M J Radford; H M Krumholz
Journal:  JAMA       Date:  2000-01-26       Impact factor: 56.272

2.  Quetiapine treatment in early psychosis: no evidence of cataracts.

Authors:  David Whitehorn; Janet Gallant; Hazel Woodley; Qing Rui; Heather Milliken; Lili Kopala
Journal:  Schizophr Res       Date:  2004-12-01       Impact factor: 4.939

3.  Twice-yearly exams unnecessary for patients taking quetiapine.

Authors:  Bruce I Gaynes
Journal:  Am J Ophthalmol       Date:  2005-08       Impact factor: 5.258

4.  Schizophrenia, psychotropic medication, and cataract.

Authors:  C A McCarty; C A Wood; C L Fu; P M Livingston; S Mackersey; Y Stanislavsky; H R Taylor
Journal:  Ophthalmology       Date:  1999-04       Impact factor: 12.079

5.  Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

Authors:  Joseph P McEvoy; Jonathan M Meyer; Donald C Goff; Henry A Nasrallah; Sonia M Davis; Lisa Sullivan; Herbert Y Meltzer; John Hsiao; T Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2005-08-30       Impact factor: 4.939

6.  Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders.

Authors:  Dan Cohen; Ronald P Stolk; Diederick E Grobbee; Christine C Gispen-de Wied
Journal:  Diabetes Care       Date:  2006-04       Impact factor: 19.112

7.  Twice-yearly exams unnecessary for patients taking quetiapine.

Authors:  Frederick W Fraunfelder
Journal:  Am J Ophthalmol       Date:  2004-11       Impact factor: 5.258

8.  Prevalence and correlates of diabetes in national schizophrenia samples.

Authors:  L Dixon; P Weiden; J Delahanty; R Goldberg; L Postrado; A Lucksted; A Lehman
Journal:  Schizophr Bull       Date:  2000       Impact factor: 9.306

9.  Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data.

Authors:  Donald R Miller; Monika M Safford; Leonard M Pogach
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

Review 10.  Physical health monitoring of patients with schizophrenia.

Authors:  Stephen R Marder; Susan M Essock; Alexander L Miller; Robert W Buchanan; Daniel E Casey; John M Davis; John M Kane; Jeffrey A Lieberman; Nina R Schooler; Nancy Covell; Scott Stroup; Ellen M Weissman; Donna A Wirshing; Catherine S Hall; Leonard Pogach; Xavier Pi-Sunyer; J Thomas Bigger; Alan Friedman; David Kleinberg; Steven J Yevich; Bonnie Davis; Steven Shon
Journal:  Am J Psychiatry       Date:  2004-08       Impact factor: 18.112

View more
  2 in total

1.  Neuroretinal Biomarkers for Schizophrenia Spectrum Disorders.

Authors:  Samuel Asanad; Hugh O'Neill; Hampton Addis; Shuo Chen; Jingtao Wang; Eric Goldwaser; Peter Kochunov; L Elliot Hong; Osamah J Saeedi
Journal:  Transl Vis Sci Technol       Date:  2021-04-01       Impact factor: 3.283

2.  Association of ocular diseases with schizophrenia, bipolar disorder, and major depressive disorder: a retrospective case-control, population-based study.

Authors:  Chun-Hao Liu; Eugene Yu-Chuan Kang; Yu-Hsiang Lin; Wei-Chi Wu; Zhuo-Hao Liu; Chang-Fu Kuo; Chi-Chun Lai; Yih-Shiou Hwang
Journal:  BMC Psychiatry       Date:  2020-10-02       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.